LEE WESLER: Open Payments
NPI 1982766325 · DAYVILLE, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,444 in 148 payments from 29 companies in 2025. Trend: 2023 $3,612 · 2024 $3,513 · 2025 $4,444
Food & beverage: $4,194Education: $250
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 23 | $590 |
| Teva Pharmaceuticals USA, Inc. | 16 | $492 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $456 |
| Novo Nordisk Inc | 14 | $403 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $378 |
| ABBVIE INC. | 15 | $298 |
| Actelion Pharmaceuticals US, Inc. | 2 | $190 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $187 |
| AstraZeneca Pharmaceuticals LP | 6 | $180 |
| PFIZER INC. | 9 | $178 |
Products named: RECORLEV, CAPLYTA, Kerendia, AUSTEDO XR, Ozempic, ELIQUIS, JARDIANCE, IBSRELA.
Industry payments across CT — which companies pay providers there.
